MIFOMELATIDE FOR CANCER CACHEXIA

Mifomelatide, a dual MC3R/MC4R antagonist, is being evaluated as a potential treatment for cachexia in patients with advanced cancer

There are currently no FDA-approved treatments for cancer cachexia

Mifomelatide, our most advanced product candidate, is being tested in a Phase 2 clinical trial to address this unmet medical need

Cachexia is a devastating wasting syndrome that can hinder patients’ ability to withstand chemotherapy and impact survival

50% of patients with cancer are affected by cachexia each year1
Up to 30% of deaths in patients with cancer are caused by cachexia2

Mifomelatide Highlights

1

Broad applicability across indications

Mifomelatide targets a conserved biological system at the root of all forms of cachexia, whether caused by cancer or other underlying chronic diseases

2

Safe in healthy adults

Phase 1 trial participants did not experience treatment-related adverse events3

3

Weight gain observed in Phase 1

Healthy adults taking mifomelatide gained 1.1 kg compared to placebo in just 5 days3

4

Phase 2 clinical trial enrolling

The Paradox trial is enrolling patients with newly diagnosed unresectable, locally advanced or metastatic colorectal cancer

1. Mariean et al. Cancers (Basel), 2023, 15, 5590.
2. Han et al. EJNMMI Res., 2021, 11, 94.
3. Qi et al. J Clin Oncol., 2023, 41, e15195.